These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38988090)

  • 1. Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea.
    Ko M; Kim S; Choi SK; Shin SH; Lee YK; Kwon Y
    Osong Public Health Res Perspect; 2024 Aug; 15(4):364-374. PubMed ID: 38988090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
    Chen C; Chen C; Cao L; Fang J; Xiao J
    Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA
    Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
    Yamin D; Yechezkel M; Arbel R; Beckenstein T; Sergienko R; Duskin-Bitan H; Yaron S; Peretz A; Netzer D; Shmueli E
    Lancet Infect Dis; 2023 Oct; 23(10):1130-1142. PubMed ID: 37352878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
    Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase.
    Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY
    J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
    Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
    Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
    Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1616-1624. PubMed ID: 36580430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
    Tenforde MW; Weber ZA; Natarajan K; Klein NP; Kharbanda AB; Stenehjem E; Embi PJ; Reese SE; Naleway AL; Grannis SJ; DeSilva MB; Ong TC; Gaglani M; Han J; Dickerson M; Fireman B; Dascomb K; Irving SA; Vazquez-Benitez G; Rao S; Konatham D; Patel P; Schrader KE; Lewis N; Grisel N; McEvoy C; Murthy K; Griggs EP; Rowley EAK; Zerbo O; Arndorfer J; Dunne MM; Goddard K; Ray C; Zhuang Y; Timbol J; Najdowski M; Yang DH; Hansen J; Ball SW; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 71(53):1637-1646. PubMed ID: 36921274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.
    Chatzilena A; Hyams C; Challen R; Marlow R; King J; Adegbite D; Kinney J; Clout M; Maskell N; Oliver J; Finn A; Danon L;
    Euro Surveill; 2023 Nov; 28(48):. PubMed ID: 38037728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Kim S; Ko M; Heo Y; Lee YK; Kwon Y; Choi SK; Bahng E
    Vaccine; 2023 Aug; 41(35):5066-5071. PubMed ID: 37422379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.
    Kim RK; Choe YJ; Jang EJ; Chae C; Hwang JH; Lee KH; Shim JA; Kwon GY; Lee JY; Park YJ; Lee SW; Kwon D
    J Korean Med Sci; 2023 Nov; 38(46):e396. PubMed ID: 38013649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
    Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J
    Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea.
    Lee YK; Kwon Y; Heo Y; Kim EK; Kim SY; Cho H; Kim S; Ko M; Lim D; Seo SY; Cho E
    Clin Exp Pediatr; 2023 Oct; 66(10):415-423. PubMed ID: 37309116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
    Sane Schepisi M
    Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.